TY - JOUR
T1 - International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer
T2 - European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations
AU - Meattini, Icro
AU - Becherini, Carlotta
AU - Caini, Saverio
AU - Coles, Charlotte E.
AU - Cortes, Javier
AU - Curigliano, Giuseppe
AU - de Azambuja, Evandro
AU - Isacke, Clare M.
AU - Harbeck, Nadia
AU - Kaidar-Person, Orit
AU - Marangoni, Elisabetta
AU - Offersen, Birgitte
AU - Rugo, Hope S.
AU - Salvestrini, Viola
AU - Visani, Luca
AU - Morandi, Andrea
AU - Lambertini, Matteo
AU - Poortmans, Philip
AU - Livi, Lorenzo
AU - Consensus Panellist Group
N1 - Funding Information:
Our sincere gratitude goes to Marco Banini, Marianna Valzano, and Pietro Garlatti from the University of Florence (Florence, Italy). We would also like to express our appreciation to Frank Vicini, Saverio Cinieri, Asal Rahimi, Maryam Garousi, Marta Perachino, Paola Francica, Chelain Goodman, Fatjona Kraja, and Alizee Camps Malea for their valuable contributions. CEC is funded by the National Institute of Health and Care Research (NIHR) and supported by the NIHR Cambridge Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. We extend our thanks to Fondazione Radioterapia Oncologica non-profit organisation and all who have provided essential support for scientific research. We also acknowledge the unconditional support of all the companies involved in the implementation of scientific research and studies, including IFCA Spa, Fondazione Cassa di Risparmio di Pistoia e Pescia, Conad Società Cooperativa, Fabiani Gioiellerie, Permira, Rinascente, and Giorgio Tesi Group. During the preparation of this work the authors used ChatGPT to improve readability and language of the work. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.
Funding Information:
Our sincere gratitude goes to Marco Banini, Marianna Valzano, and Pietro Garlatti from the University of Florence (Florence, Italy). We would also like to express our appreciation to Frank Vicini, Saverio Cinieri, Asal Rahimi, Maryam Garousi, Marta Perachino, Paola Francica, Chelain Goodman, Fatjona Kraja, and Alizee Camps Malea for their valuable contributions. CEC is funded by the National Institute of Health and Care Research (NIHR) and supported by the NIHR Cambridge Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. We extend our thanks to Fondazione Radioterapia Oncologica non-profit organisation and all who have provided essential support for scientific research. We also acknowledge the unconditional support of all the companies involved in the implementation of scientific research and studies, including IFCA Spa, Fondazione Cassa di Risparmio di Pistoia e Pescia, Conad Società Cooperativa, Fabiani Gioiellerie, Permira, Rinascente, and Giorgio Tesi Group. During the preparation of this work the authors used ChatGPT to improve readability and language of the work. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.
Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024/2
Y1 - 2024/2
N2 - Novel systemic therapies for breast cancer are being rapidly implemented into clinical practice. These drugs often have different mechanisms of action and side-effect profiles compared with traditional chemotherapy. Underpinning practice-changing clinical trials focused on the systemic therapies under investigation, thus there are sparse data available on radiotherapy. Integration of these new systemic therapies with radiotherapy is therefore challenging. Given this rapid, transformative change in breast cancer multimodal management, the multidisciplinary community must unite to ensure optimal, safe, and equitable treatment for all patients. The aim of this collaborative group of radiation, clinical, and medical oncologists, basic and translational scientists, and patient advocates was to: scope, synthesise, and summarise the literature on integrating novel drugs with radiotherapy for breast cancer; produce consensus statements on drug-radiotherapy integration, where specific evidence is lacking; and make best-practice recommendations for recording of radiotherapy data and quality assurance for subsequent studies testing novel drugs.
AB - Novel systemic therapies for breast cancer are being rapidly implemented into clinical practice. These drugs often have different mechanisms of action and side-effect profiles compared with traditional chemotherapy. Underpinning practice-changing clinical trials focused on the systemic therapies under investigation, thus there are sparse data available on radiotherapy. Integration of these new systemic therapies with radiotherapy is therefore challenging. Given this rapid, transformative change in breast cancer multimodal management, the multidisciplinary community must unite to ensure optimal, safe, and equitable treatment for all patients. The aim of this collaborative group of radiation, clinical, and medical oncologists, basic and translational scientists, and patient advocates was to: scope, synthesise, and summarise the literature on integrating novel drugs with radiotherapy for breast cancer; produce consensus statements on drug-radiotherapy integration, where specific evidence is lacking; and make best-practice recommendations for recording of radiotherapy data and quality assurance for subsequent studies testing novel drugs.
KW - OPEN-LABEL
KW - CONCURRENT TRASTUZUMAB
KW - RADIATION-THERAPY
KW - MULTICENTER
KW - CHEMOTHERAPY
KW - PALBOCICLIB
KW - COMBINATION
KW - PEMBROLIZUMAB
KW - FULVESTRANT
KW - PERTUZUMAB
U2 - 10.1016/S1470-2045(23)00534-X
DO - 10.1016/S1470-2045(23)00534-X
M3 - (Systematic) Review article
SN - 1470-2045
VL - 25
SP - e73-e83
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 2
ER -